Introduction {#sec1}
============

*Candida albicans* is the most frequently isolated fungal species from human as either commensal or pathogen \[[@bib1]\]. The population structure difference is crucial in describing the epidemiology, genetic dynamics and diversity of *C. albicans*. Multilocus sequence typing (MLST) has a high discriminatory power and interlaboratory reproducibility in the detection of pathogen population structure differences \[[@bib2]\]. The high discriminatory power of *C. albicans* MLST is associated with its ability to detect the polymorphic nucleotide sites in these genes \[[@bib2], [@bib3], [@bib4]\]. The allelic difference combinations at different loci in MLST results in the development of unique sequence types (STs) which discriminate different strains \[[@bib2]\].

Worldwide, *C. albicans* diploid sequence type (DST) 69 has been reported to be the leading cause of both invasive and noninvasive infection \[[@bib5]\]. However, geographical variations of *C. albicans* genotypes causing different clinical conditions in susceptible individuals have been reported \[[@bib6]\]. DST79, DST69 and DST155 have been found to be more common in Africa than other continents (<https://pubmlst.org/calbicans/>). Furthermore, the DST ST3 or ST16 have been associated with reduced susceptibility to azole antifungal \[[@bib7],[@bib8]\]. As a result of limited data on ST of *C. albicans* causing different clinical conditions in Africa and the overuse of over-the-counter antifungal treatments \[[@bib9]\], it is still not clear whether *Candida albicans* strains in Africa have local or international distributions.

This study was conducted to determine the distribution patterns of *C. albicans* STs causing different clinical conditions in Mwanza, Tanzania, using MLST.

Methods {#sec2}
=======

Strain set {#sec2.1}
----------

The current study used 64 archived *Candida albicans* isolates from a previous cross-sectional study that was conducted between January and December 2017 at the Bugando Medical Centre \[[@bib10]\]. *C. albicans* isolated from patients with oral thrush (*n* = 9), vaginal candidiasis (11), candiduria (29), esophageal candidiasis (12) and blood candidiasis (3) were included in this study. The selected isolates were previously tested for susceptibility to fluconazole, voriconazole and posaconazole (Discovery Fine Chemicals, Bournemouth, UK), using European Committee on Antimicrobial Susceptibility Testing (EUCAST) minimum inhibitory concentration broth microdilution \[[@bib10]\]. The study included all *C. albicans* with reduced susceptibility to azole antifungal agents. The reduced susceptibility to azole antifungal was based on the increase in epidemiologic cutoff value for azole antifungal agents compared to values in the literature, as documented in a previous study \[[@bib10]\].

Five *C. albicans* isolates had increased MIC values on the initial testing using broth microdilution; however, only two isolates were confirmed by repeating broth microdilution and Etest.

MLST procedure {#sec2.2}
--------------

Frozen isolates were subcultured on Sabouraud dextrose agar (Oxoid, Basingstoke, UK) and aerobically incubated at 37°C for 24 hours. Genomic DNA was extracted by the phenol--chloroform method as previously described \[[@bib11]\]. The purity of the extract was tested using the NanoDrop spectrophotometer (NanoDrop 2000c, Thermo Fisher Scientific, Waltham, MA, USA). An extract with absorbance ratio of 1.8 (280/260) and above was considered to be pure DNA extract.

The scheme developed by Bougnoux et al. \[[@bib2]\] was used for MLST. The amplification of the seven housekeeping genes was performed using primers listed in [Table 1](#tbl1){ref-type="table"} \[[@bib2]\]. The PCR was carried out in 45 μL volume containing Ampli Taq DNA polymerase 0.5 μL (5 U/μL), PCR buffer 5 μL, 0.5 μL deoxynucleoside triphosphate (dNTP) 0.1mM, 3 μL each of the primers (Qiagen, Hilden, German), 34 μL PCR water and 2 μL of DNA template \[[@bib2]\].Table 1Gene fragments of *Candida albicans* used for multilocus sequence typingTable 1GenePrimer sequenceSequence basesGene product*AAT1a*F-5′-ACTCAAGCTAGATTTTTGGC-3′373Aspartate aminotransferaseR-5′-CAGCAACATGATTAGCCC-3′*AAC1*F-5′-GCAAGAGAAATTTTAATTCAATG-3′407Acetylcoenzyme A carboxylaseR-5′-TTCATCAACATCATCCAAGTG-3′*ADP1*F-5′-GAGCCAAGTATGAATGATTTG-3′443ATP-dependent permeaseR-5′-TTGATCAACAAACCCGATAAT-3′*MP1b*F-5′-ACCAGAAATGGCCATTGC-3′375Mannose phosphate dehydrogenaseR-5′-GCAGCCATGCATTCAATTAT-3′*SYA1*F-5′- AGAAGAATTGTTGCTGTTACTG-3′391Alanyl-RNA synthetaseR-5′-GTTACCTTTACCACCAGCTTT-3′*VPS13*F-5′-TCGTTGAGAGATAATCGACTT-3′403Vacuolar protein sorting proteinR-5′-ACGGATGGATCTCCAGTCC-3′*ZWF1a*F-5′-GTTTCATTTGATCCTGAAGC-3′491Glucose-6-phosphate dehydrogenaseR-5′-GCCATTGATAAGTACCTGGAT-3′R-5′-AATTCGGTTGTAAGATGATGTTGC-3′

PCR conditions were as follows: 95°C for 15 minutes for initial denaturation, followed by 30 cycles of denaturation at 95°C for 30 seconds, annealing at 57°C for 30 seconds, extension at 72°C for 2 minutes and final extension at 72°C for 10 minutes. To confirm amplification, 5 μL of amplicon was visualized on 1% agarose gel in a Tris--acetate EDTA buffer.

The DNA amplicon was purified using a Qiagen purification kit followed by DNA Sanger sequencing (Seqlab-Microsynth, Göttingen, Germany) using same primers listed in [Table 1](#tbl1){ref-type="table"}. Analysis of sequences was carried as described in *C. albicans* database (<https://pubmlst.org/calbicans/>). The maximum-likelihood tree was constructed based on concatenated DNA sequences of seven loci using Geneious 11 software (Biomatters, Auckland, New Zealand).

Ethical clearance for conducting this study was granted by a joint CUHAS/BMC research ethics and review committee (certificate no. CREC/280/2017).

Results {#sec3}
=======

A total of 3953 bp were sequenced in seven loci of each nonrepetitive *Candida albicans* isolate ([Table 1](#tbl1){ref-type="table"}). Forty-eight STs were obtained, resulting in 75% population structure differences. A total of 27 new STs were detected in 29 *C. albicans* isolates. The 29 *C. albicans* isolates were from high vaginal swabs (*n* = 3, 10.3%), urine (*n* = 12, 41.4%), blood/esophageal brushes (*n* = 8, 27.6%) and oral swabs (*n* = 6, 20.7%) ([Table 2](#tbl2){ref-type="table"}). Of the 35 *C. albicans* with known STs, 21 diploid STs were assigned.Table 2Novel MLST sequence typesTable 2Sample no.IsolateDST*AATACC1aADPMP1bSYAVPSZWF*1V066354033732262612952V0233542335357102183V0563543235922054V0593544814837385V0603545557836452496V06435468364710897V07535475514426645158V0773548337323261489V09235495514426451210V0943550835926511V103355180144324451512V105355243148474458913V106355358766760814V107355411266471011915V10835558148273816V1093556354463424417V1113557393636451518V112[a](#tbl2fna){ref-type="table-fn"}35583536364524919V1173539814842383820V146355947167194191421V15835605514432451522V1803561814847108923V210356247352281830624V268[a](#tbl2fna){ref-type="table-fn"}3563255266525V336356421325938651226V3473565235223424727V38635665576334512[^1][^2]

On the basis of the STs, the isolates with new STs were significantly more diverse than the *C. albicans* isolates with known STs (27/29, 93.1% vs. 21/35, 60%, p 0.002). The most frequently detected STs were DST124, DST365 and DST3126, each of which was observed in four isolates, followed by DST69, with three isolates ([Table 3](#tbl3){ref-type="table"}).Table 3Antifungal susceptibility pattern of *Candida albicans* stratified by sequence typeTable 3Isolate IDDSTIsolation yearSampleAge (years)FLVRPOCAMI5-FCV0065742016High vaginal swab250.250.0040.0160.1250.0630.031V0155192016High vaginal swab304 (0.094)0.125 (0.006)4 (0.008)0.1250.0080.5V0203112016High vaginal swab290.250.250.0160.0630.50.031V021692016High vaginal swab300.250.0040.0160.0630.0160.25V02335422016High vaginal swab190.250.0040.0160.12520.063V048692016High vaginal swab1616 (0.125)0.004 (0.008)0.016 (0.012)0.0310.1250.5V051792016Urine160.250.0040.0080.0630.0630.5V05635432016Urine230.250.1250.0160.0080.0310.25V05716242016Urine230.250.1250.0160.0630.0630.063V05935442016Urine210.250.0040.0160.0310.0310.25V06035452016Urine200.250.0040.0160.0630.0310.25V061522016Urine180.250.0040.0160.0630.0630.063V06435462016Urine200.250.0040.0160.0080.1250.125V0659162016Urine220.250.0040.0160.0040.0630.125V06635402016Urine200.250.0040.0080.0160.0630.5V06733302016Urine208 (8.000)0.016 (0.75)0.063 (0.064)0.0080.0630.125V06917552016Urine200.250.1250.0160.250.0630.063V07017552016Urine200.250.1250.0160.250.0630.063V0731242016Urine90.250.1250.0160.1250.0630.063V07535472016Urine70.250.0040.0160.250.0630.5V07735482016Urine530.250.0040.0160.250.0630.063V0783652016Urine90.250.1250.0310.1250.0630.125V0853652016Urine530.250.0040.0160.250.0630.063V0883652016Urine470.250.0040.0160.250.0630.063V0893652016Urine530.250.0630.0160.250.0630.125V09235492016Urine280.250.0040.0160.250.0630.031V09435502016Urine210.250.0040.0160.1250.0630.125V0971242016Urine350.250.0310.0040.250.0630.063V1001242016Urine310.250.1250.0160.1250.0310.063V1012992016Urine250.250.0040.0160.250.1250.063V10335512016Urine340.250.1250.0310.250.0630.063V10535522017Blood3m0.250.0040.0080.250.0630.063V10635532017Blood10.250.1250.0310.1250.0310.063V10735542017Blood10.250.0040.0160.250.0630.063V10835552017Esophageal brush830.50.0040.0310.250.0630.063V10935562017Esophageal brush720.250.0040.0160.250.0630.063V11135572017Esophageal brush540.250.1250.0630.1250.0630.063V11235582017Esophageal brush300.250.0040.0080.1250.0630.063V1147592017Esophageal brush230.250.0080.0020.1250.0630.063V1157592017Esophageal brush600.250.1250.0160.250.0630.063V1169272017Esophageal brush480.250.0040.0020.1250.0630.063V11735392016Urine200.250.0040.0020.250.0630.063V1189272016Urine270.250.0040.0020.250.0310.031V12331262016Urine360.250.0040.0310.1250.0630.063V1381242016Oral swab20.250.250.0160.1250.0630.063V14310752016Oral swab8256 (0.190)32 (0.008)0.125 (0.012)0.0040.1250.063V14635592016Oral swab30.250.50.0310.0310.0630.063V15835602016Oral swab20.250.250.0160.1250.0630.125V1791442017Esophageal brush590.250.0040.0160.1250.0630.5V18035612017Esophageal brush430.250.0040.0160.250.0630.063V18131262017Esophageal brush820.250.0040.0310.50.0630.063V21035622015Oral swab140.250.0040.0310.250.0630.063V227692016High vaginal swab241 (4)0.004 (0.094)0.063 (0.25)0.1250.0630.063V26835632016High vaginal swab240.250.0040.0160.1250.0160.5V27635632016High vaginal swab3940.1250.250.1250.0310.063V27827572016High vaginal swab310.250.0040.0160.1250.0160.125V28031262016High vaginal swab380.250.0310.1250.1250.1250.063V29431262015Esophageal brush510.250.250.0160.250.0310.063V2952772015Esophageal brush520.25320.250.0040.0311V33635642015Oral swab450.50.0250.1250.0020.0310.063V34735652015Oral swab411640.50.1250.5V35027162016Oral swab820.250.0310.0310.250.0630.063V38635662015Oral swab140.250.0040.0160.250.0630.125V39735582016Urine420.250.0310.0310.1250.0630.063[^3][^4]

Discussion {#sec4}
==========

The 64 *C. albicans* clinical isolates from different samples were typed in 48 distinct DST, indicating 75% diversity of these isolates. The observed high population structure difference could be explained by the heterozygosity of the diploid *C. albicans* genome, which contributes to a high rate of genetic exchange \[[@bib4]\]. The high population structure difference observed in the current study is similar to what was observed previously by Wu *et* al. \[[@bib12]\] among clinical *C. albicans* isolates from sputum and urine samples, and by Ge *et* al. \[[@bib13]\] among *C. albicans* isolated from urogenital samples in China. Furthermore, the observed difference is higher than that observed among *C. albicans* causing healthcare-associated bloodstream infections in United States \[[@bib14]\]. The differences in the nature of the clinical samples and study setting explain the observed differences \[[@bib15]\]. The current study involved *C. albicans* isolates from diverse specimens, which therefore has a greater likelihood of having diverse DSTs compared to the study from the United States, which studied *C. albicans* isolated from blood samples in the hospital setting.

As has been observed previously by different studies \[[@bib2],[@bib8],[@bib16]\], DST69 was among the frequently observed STs in the current study. DST69 was also the most frequently detected genotype from noninvasive samples in Morocco (<https://pubmlst.org/calbicans/>). This observation confirms that DST69 is a globally distributed *C. albicans* genotype ([Fig. 1](#fig1){ref-type="fig"}).Fig. 1*Candida albicans* genotype distributions. Maximum-likelihood tree was constructed based on concatenated DNA sequences of seven loci using Geneious R11 (Biomatters, Auckland, New Zealand) showing multilocus sequence typing--based phylogenetic relationship of all *C. albicans* isolates contained in study.Fig. 1

A number of new DSTs were observed among *C. albicans* isolates in this study. Furthermore, it was observed that *C. albicans* with new DSTs were more diverse than those with known DST. This confirms that *Candida albicans* from different geographical location are likely to display distinct DSTs \[[@bib7],[@bib8]\]. The variation also confirms the ability of *C. albicans* MLST systems to detect minor genetic changes \[[@bib16],[@bib17]\]. The geographical variation of *C. albicans* has also been observed among isolates from other African countries (<https://pubmlst.org/calbicans/>). The observed high variations of genotypes in Tanzania is similar to previous studies in China which reported 79% and 82% new DST among *Candida albicans* studied \[[@bib12],[@bib13]\].

Conclusions {#sec5}
===========

*C. albicans* from clinical specimens were highly diverse, with a number of new DSTs that had not been previously reported in the MLST world database. This confirms the presence of genetic differences of *C. albicans* in different geographical regions. Because of the high diversity of genotypes, we need to develop robust point-of-care techniques to genotype *C. albicans* isolates, especially those causing invasive infection.
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[^1]: DST, diploid sequence type; MLST, multilocus sequence typing.

[^2]: Two isolates had similar sequence type for each.

[^3]: All values European Committee on Antimicrobial Susceptibility Testing (EUCAST) edef7.2, except those in parentheses (Etest; bioMérieux, Marcy l'Étoile, France).

[^4]: CA, caspofungin; DST, diploid sequence type; FL, fluconazole; MI, micafungin; PO, posaconazole; VR, voriconazole.
